Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon In-Licenses Diabetes Med from France’s Poxel
November 1, 2017
- Astellas’ Half-Year Operating Profit Down 38.8% on LLP Divestiture, Micardis Gx Erosion
November 1, 2017
- Global Sales of Shionogi’s Novel Influenza Drug Could Reach US$1 Billion: President
November 1, 2017
- Parkinson’s Disease Therapy Rasagiline Improves Average Daily Off-Time in Japan PII/PIII Study: Takeda
November 1, 2017
- Daiichi Sankyo Pairs Up with German Startup to Develop ADC for Solid Cancer
November 1, 2017
- Boehringer, Astellas to Extend Sales Pact for Micardis Family of Products to March 2020
November 1, 2017
- Sumitomo Dainippon Beats 1st Half Guidance, Ups Full-Year Outlook
October 31, 2017
- Shionogi Notches Double-Digit Sales Rise on HIV/Flu Royalties
October 31, 2017
- JT, Torii to Jointly Develop HIF-PH inhibitor in Japan
October 30, 2017
- JCR Starts Development of Another BBB-Penetrating Drug for Hurler Syndrome
October 30, 2017
- Mogamulizumab Accepted for Review in Europe: Kyowa Kirin
October 30, 2017
- JSR Grabs License to Gut Bacteria Research Outcome by Keio Univ./Univ. of Tokyo, I/O Drug Discovery Eyed
October 30, 2017
- Crestor Generics of Sawai, Pfizer to Get Listed with Full Indications
October 27, 2017
- Eisai Ups Profit Estimates for April-September
October 27, 2017
- Ono Lifts Half-Year Guidance on Opdivo Boon
October 27, 2017
- Mitsubishi Tanabe Withdraws Petitions for Injunction against 3 Generic Makers Over Talion Patent Infringement
October 27, 2017
- Fujifilm Invests in Japan Biomedical to Boost Regenerative Medicine Business
October 27, 2017
- Novartis Seeks SJIA Indication for Ilaris in Japan
October 26, 2017
- Shionogi’s Sakigake-Designated Flu Med Filed in Japan
October 26, 2017
- Parmodia, Canalia Climb GP Recollection Ranking in August: Anterio
October 25, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…